(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 71.27%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.09%.
Longeveron's earnings in 2025 is -$21,341,000.On average, 6 Wall Street analysts forecast LGVN's earnings for 2025 to be -$32,204,117, with the lowest LGVN earnings forecast at -$30,941,211, and the highest LGVN earnings forecast at -$33,151,297. On average, 6 Wall Street analysts forecast LGVN's earnings for 2026 to be -$28,613,793, with the lowest LGVN earnings forecast at -$34,495,269, and the highest LGVN earnings forecast at -$21,951,535.
In 2027, LGVN is forecast to generate -$36,120,834 in earnings, with the lowest earnings forecast at -$34,704,331 and the highest earnings forecast at -$37,183,212.